INVO Fertility operates in the assisted reproductive technology market through a diversified business model spanning medical devices, clinical services, and therapeutic development. The company's flagship product is the INVOcell Device, a medical device designed to enable fertilization and early embryo development to occur in vivo within a woman's body, differentiating its approach from traditional in vitro fertilization methods. The company also operates fertility clinics under the INVO Centers brand, providing direct patient care services.
The company organizes its operations across three segments: Fertility Clinic Services, the INVOcell Device business, and Therapeutics. Within the therapeutics division, INVO Fertility is developing NY-303, a GPC3 x NKp46 bifunctional antibody currently in Phase I/IIa monotherapy trials for hepatocellular carcinoma, and NY-500, an AI-optimized bifunctional antibody candidate.
Based in Sarasota, Florida, INVO Fertility operates with a staff of 33 full-time employees. The company was incorporated in Nevada and is listed on Nasdaq. Originally founded in 2007 as NAYA Biosciences, Inc., the company rebranded to INVO Fertility in April 2025, reflecting its strategic focus on the fertility marketplace and its portfolio of reproductive technology and therapeutics offerings.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-30.19 | $-30.19 | -488.5% | |
| 2023 | $-5.13 | $-5.13 | -470.0% | |
| 2022 | $-0.90 | $-0.90 | -42.9% | |
| 2021 | $-0.63 | $-0.63 | +58.6% | |
| 2020 | $-1.52 | $-1.52 | -15100.0% | |
| 2019 | $-0.01 | $-0.01 | +50.0% | |
| 2018 | $-0.02 | $-0.02 | — | |
| 2017 | $0.00 | $0.00 | +100.0% | |
| 2016 | $-0.02 | $-0.02 | +50.0% | |
| 2015 | $-0.04 | $-0.04 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-04-30 | 0001641172-25-006726 | SEC ↗ |
| 2023-12-31 | 2024-04-16 | 0001493152-24-014838 | SEC ↗ |
| 2022-12-31 | 2023-04-17 | 0001493152-23-012532 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001493152-22-008421 | SEC ↗ |
| 2020-12-31 | 2021-03-30 | 0001185185-21-000413 | SEC ↗ |
| 2019-12-31 | 2020-03-30 | 0001185185-20-000388 | SEC ↗ |
| 2018-12-31 | 2019-04-16 | 0001185185-19-000550 | SEC ↗ |
| 2017-12-31 | 2018-03-29 | 0001185185-18-000521 | SEC ↗ |
| 2016-12-31 | 2017-04-20 | 0001185185-17-000969 | SEC ↗ |
| 2015-12-31 | 2017-03-17 | 0001185185-17-000595 | SEC ↗ |
| 2010-12-31 | 2011-04-15 | 0001185185-11-000506 | SEC ↗ |
| 2009-12-31 | 2010-04-06 | 0001185185-10-000369 | SEC ↗ |
| 2008-12-31 | 2009-04-15 | 0001185185-09-000334 | SEC ↗ |